Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Co-Infected Populations

Two Standards of Care

While improved treatments are necessary for all people living with hepatitis C, this is particularly true for people who are living with HIV/HCV co-infection. Procedural and institutional barriers have resulted in two standards of care – one for people living with mono-infection, and a much worse standard for people living with co-infection. This position paper explains why these two standards of care have emerged and makes pragmatic recommendations to accelerate clinical trials and Common Drug Review decision-making to allow co-infected people to benefit from the latest technologies available.

This position paper explains:

 

  • How clinical trial designs often cause unnecessary delays in evaluating the safety and efficacy of newhepatitis C treatments for people who are living with co-infection
  • How health technology assessment organizations like the Common Drug Review, as well as public formularies, exacerbate these delays by limiting coverage for co-infected people, preventing doctors from doing what is right for their patients.
  • Pragmatic changes that can be made to clinical trial designs and health technology assessment decision-making that will assure timely access and equitable treatment for people living with co-infection

 

Read and download the report here.

 

 

Creative Commons License
Two Standards of Care: Toward Treatment Equity for People Living With HIV/HCV Co-Infection by Paul Sutton is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.